BridgeBio Oncology Therapeutics (BBOT) Preferred Stock Liabilities (2024 - 2025)

BridgeBio Oncology Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $196.5 million in Q2 2025.

• Quarterly Preferred Stock Liabilities rose 4.72% year-over-year to $196.5 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $196.5 million (up 4.72% YoY) and the FY2024 annual result came in at $192.4 million, changed N/A from the prior year.
• Preferred Stock Liabilities climbed to $196.5 million in Q2 2025 per BBOT's latest filing, from $194.4 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $196.5 million in Q2 2025 and troughed at $185.2 million in Q1 2024.